'Aggressive launch' planned for new combo in first-line kidney cancer

exelixis-big-1

Impressive data for another immuno-oncology / tyrosine kinase inhibitor (TKI) combo add up to yet more competition in the first-line kidney cancer setting.

Exelixis (Nasdaq: EXEL) and Bristol Myers Squibb (NYSE: BMY) outlined detailed results for a combination of Cabometyx (cabozantinib) and Opdivo (nivolumab), during a Presidential Symposium of the European Society for Medical Oncology (ESMO) annual congress.

Ahead of the presentation, Exelixis chief executive Michael Morrissey tells The Pharma Letter they were: "Great results,” and: “Really wonderful data.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology